<DOC>
	<DOCNO>NCT00453154</DOCNO>
	<brief_summary>This partially randomized phase I/II trial study side effect best dose sunitinib malate see well work give together cisplatin carboplatin etoposide treat patient extensive-stage small cell lung cancer . Drugs use chemotherapy , cisplatin , carboplatin , etoposide , work different way stop growth tumor cell , either kill cell stop dividing . Sunitinib malate may stop growth tumor cell block enzymes need cell growth block blood flow tumor . It yet know whether cisplatin carboplatin etoposide effective give without sunitinib malate treat small cell lung cancer .</brief_summary>
	<brief_title>Cisplatin Carboplatin , Etoposide With Without Sunitinib Malate Treating Patients With Extensive-Stage Small Cell Lung Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine phase II dose sunitinib ( sunitinib malate ) combine cisplatin etoposide . ( Phase IB ) II . To compare progression-free survival patient extensive stage small cell lung cancer treat cisplatin carboplatin etoposide follow maintenance sunitinib patient receive chemotherapy follow placebo . ( Phase II ) SECONDARY OBJECTIVES : I . To assess single agent response rate sunitinib give monotherapy chemotherapy . ( Phase II ) II . To assess overall survival patient treat cisplatin carboplatin etoposide follow sunitinib . ( Phase II ) III . To evaluate toxicity tolerability maintenance sunitinib cisplatin carboplatin etoposide . ( Phase II ) IV . To determine association vascular endothelial growth factor ( VEGF ) plasma level tumor response . ( Phase II ) OUTLINE : This phase I , dose-escalation study sunitinib malate follow randomized phase II study . PHASE I ( close accrual 5/17/08 ) : COMBINATION THERAPY : Patients receive cisplatin carboplatin intravenously ( IV ) day 1 , etoposide IV day 1-3 , sunitinib malate orally ( PO ) daily ( QD ) day 1-14 . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . MAINTENANCE THERAPY : Patients receive sunitinib malate PO alone QD . Treatment continue absence disease progression unacceptable toxicity . PHASE II : COMBINATION THERAPY : Patients receive cisplatin carboplatin etoposide Phase I . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . MAINTENANCE THERAPY : Beginning 3-8 week completion combination chemotherapy &gt; = 4 course combination therapy , patient respond stable disease randomize 1 2 treatment arm . All patient must euthyroid start maintenance therapy . ARM I : Patients receive sunitinib malate PO QD . Courses repeat every 3 week absence disease progression unacceptable toxicity . ARM II : Patients receive placebo PO QD . Courses repeat every 3 week absence disease progression unacceptable toxicity . Patients disease progression may cross Arm I . After completion study treatment , patient follow every 3 month 1 year every 6 month 2 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>All patient must histologically cytologically document small cell lung cancer Eligible disease stage : extensive disease classification protocol include patient disease site define limited stage ; limited stage disease category include patient disease restrict one hemithorax regional lymph node metastasis , include hilar , ipsilateral contralateral mediastinal , and/or ipsilateral supraclavicular node ; extensive stage patient define patient extrathoracic metastatic , malignant pleural effusion , bilateral contralateral supraclavicular adenopathy contralateral hilar adenopathy All patient must measurable disease : Measurable disease define least one lesion accurately measure least one dimension ( long diameter record ) &gt; = 20 mm conventional technique &gt; = 10 mm spiral compute tomography ( CT ) scan Lesions consider nonmeasurable , would make patient eligible , include follow : Bone lesion Leptomeningeal disease Ascites Pleural/pericardial effusion Lymphangitis cutis/pulmonis Abdominal mass confirm followed imaging technique Cystic lesion No prior chemotherapy small cell lung cancer ( SCLC ) Radiation therapy must complete least one week initiation protocol therapy Common Toxicity Criteria ( CTC ) performance status : Phase IB : 01 Phase II : 02 No `` currently active '' second malignancy nonmelanoma skin cancers No history brain metastasis , spinal cord compression , carcinomatous meningitis No ongoing cardiac dysrhythmias , atrial fibrillation , QTc interval &gt; = 500 msec ; use agent proarrhythmic potential ( e.g. , quinidine , procainamide , disopyramide , sotalol , probucol , pedridel , haloperidol , risperidone , indapamide , flecainide ) recommend protocol therapy Patients class I New York Heart Association ( NYHA ) eligible ; patient history class II NYHA eligible , provide meet follow criterion : Patients history class II heart failure asymptomatic treatment Patients prior anthracycline exposure Patients receive central thoracic radiation include heart radiotherapy port Patients history class III IV NYHA heart failure within 12 month prior registration eligible Additionally , myocardial infarction , severe/unstable angina , coronary/peripheral artery bypass graft stenting , cerebrovascular accident include transient ischemic attack , pulmonary embolism within last year Patients hypertension control medication ( &gt; 150/100 mmHg despite optimal medical therapy ) eligible Patients require use therapeutic dos coumarinderivative anticoagulant warfarin exclude , although dos 2 mg daily permit prophylaxis thrombosis ; Note : Low molecular weight heparin permit provided patient 's prothrombin time ( PT ) international normalize ratio ( INR ) = &lt; 1.5 No evidence hemoptysis within 4 week prior start study treatment ; patient bloodtinged blood streak sputum permit study hemoptysis amount less 5 mL blood per episode le 10 mL blood per 24hour period best estimate investigator None follow within 28 day treatment : abdominal fistula , gastrointestinal perforation , intraabdominal abscess , serious nonhealing wound , ulcer , bone fracture The use follow specific inhibitor inducer cytochrome p450 , family 3 , subfamily A , polypeptide 4 ( CYP3A4 ) permit ; follow inhibitor CYP3A4 prohibit within 7 day treatment sunitinib : azole antifungal ( ketoconazole , itraconazole ) , diltiazem , clarithromycin , erythromycin , verapamil , delavirdine , human immunodeficiency virus ( HIV ) protease inhibitor ( indinavir , saquinavir , ritonavir , atazanavir , nelfinavir ) ; follow inducer CYP3A4 prohibit within 12 day begin treatment sunitinib : rifampin , rifabutin , carbamazepine , phenobarbital , phenytoin , St. John 's Wort , efavirenz , tipranavir Other inhibitor inducer CYP3A4 may use necessary , use discourage Nonpregnant nonnursing Granulocytes &gt; = 1,500/ul Platelets &gt; = 100,000/ul Creatinine clearance &gt; = 70 ml/min Total bilirubin = &lt; 1.5 mg/dl Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) = &lt; 2.5 x upper limit normal ( ULN ) ( patient w/ liver metastasis may AST/ALT = &lt; 5 x ULN ) Partial thromboplastin time ( PTT ) = &lt; 1.5 x ULN</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>